|
市場調查報告書
貧血症市場：生技學名藥及第2代產品的變化
The Anemia Market: Biogenerics and Second-Generation Products Drive Change
|
本報告已在2011年12月21日停止出版。
隨著生技重組藥物的登場，貧血症的治療雖然大幅改變和創新，但參與其中的企業仍舊是少數。而目前生技重組藥物因為給藥方式不便，加上價格居高不下，給了開發改良版藥物企業進入該市場的機會。
專門於醫療產業相關廣泛調查的美國市調公司 Decision Resources Inc. （總公司：麻薩諸塞州），針對貧血症進行調查分析，並系統整理調查結果後出版報告書 "The Anemia Market: Biogenerics and Second-Generation Products Drive Change" 。
本報告書內容包括：貧血症原因及治療法、美國、歐洲及日本目前的市場動向、新興治療方法、生技學名藥的趨勢、法規限制環境等市場的未來發展預測。共計16頁的內容綱要摘記如下：
實施概要
序章
貧血症的原因
治療方法
目前的市場
新興的治療方法
針對生技學名藥的法規限制
市場發展預測
新市場領袖的出現
表
- 2005年紅血球生成素的銷售金額
- 貧血症治療用臨床發展中的產品
- 貧血症治療用臨床發展中的生技學名藥紅血球生成素產品：歐洲
圖
- 紅血球製造
- 貧血症市場中主要參與企業的市場占有率：2005年
- 美國基因重組型紅血球生成素產品的銷售額：2000年∼2005年
Abstract
Introduction:
The availability of recombinant biologic agents has revolutionized the
treatment of anemia and has created a market with a small number of players.
However, the inconvenient administration and high prices of these biologic
agents represent an opportunity for companies to enter this market with
improved alternatives.
Get the Answers You Need to Shape Your Strategy:
- Worldwide sales of erythropoiesis-stimulating proteins reached $11.2
billion in 2005, and the market has grown annually at a rate of 13.5% since
2000. Which agents are driving the growth of the anemia market in the
United States, Europe, and Japan, and what recent changes have established new
market leaders?
- Several therapies are in development for the treatment of anemia. Which
emerging agents are likely to enjoy strong uptake, and which companies are
likely to become key players in the anemia market?
- Although many older protein therapeutics have lost patent protection, the
road to the launch of biogeneric products (also referred to as biosimilars)
has been long and complex. What are the regulatory and manufacturing
obstacles to the launch of biogenerics? Which companies are currently
developing biogeneric products?
- The potential launch of Roche' s Mircera, in development for the treatment
of anemia, has sparked a legal battle with Amgen. What strategy is Amgen
pursuing to block Roche' s launch of Mircera in the United States, and how has
Roche responded?
Scope:
- Causes of anemia: erythrocyte production, hemoglobin and oxygen
transport, and the six common forms of anemia.
- Treatment options: treatments for the most common forms of anemia.
- Current market: sales of agents to treat anemia in the United
States, Europe, and Japan.
- Emerging therapies: new biologics and small-molecule therapeutics.
- Biogenerics: regulatory hurdles, pricing, and biogeneric EPO
products.
- Market outlook: market outlook and the emergence of new market
leaders in the United States, Europe, and Japan.
Companies Mentioned in This Spectrum Report
- Affymax
- Amgen
- Astellas
- Barr
- Bioceuticals
- BioGenerix
- BioPartners
- Centocor
- Chugai
- Neose
- Fibrogen
- Fresenius Medical Care
- GeneMedix
- Hospira
- JCR
- Johnson & Johnson
- Kirin
- Kissei
- LG Life Sciences
- Mayne
- Pliva
- ProMetic
- Roche
- Sandoz
- Sanofi-Aventis
- Shire
- Stada
- Syntonix
- Takeda
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Causes of Anemia
- Treatment Options
- Current Market
- United States
- Europe
- Japan
- Emerging Therapies
- New Biologics
- Roche/Chugai' s Mircera
- Affymax/Takeda' s Hematide
- Neose' s NE-180
- Small-Molecule Therapeutics
- Fibrogen/Astellas' s FG-2216
- ProMetic' s PBI-1402
- Biogenerics
- Regulatory Hurdles to Biogenerics
- Pricing
- Biogeneric EPO Products
- Market Outlook
- United States
- Europe
- Japan
- Emergence of New Market Leaders
Tables:
- 1. Sales of Erythropoietin Products, 2005
- 2. Products in Clinical Development for the Treatment of Anemia
- 3. Biogeneric Erythropoietin Products in Development for the Treatment of
Anemia- Europe
Figures:
- 1. Erythropoiesis
- 2. Market Share of Key Players in the Anemia Market, 2005
- 3. U.S. Sales of Recombinant Erythropoietin Products, 2000-2005
|
